Strategic site selection for dermatology and rheumatology clinical trials, based on relevant experience in your indication, positive indicators in efficacy assessments, and proven recruitment track records.
By carefully selecting the right sites for your clinical trial, sponsors can expect reliable data, timely recruitment, and cost-effective study management. Inderoâs team of site selection specialists is always working on finding the best sites to increase our extensive dermatology and rheumatology site database. Hereâs how we work:
(1) Site ListÂ
Evaluate your study protocol with a cross-functional team to fully understand site requirements and core competencies.
Develop site selection strategy, including recruitment objectives and projections based on competitive landscape, timelines, and sitesâ past performance metrics.
Create a site list and an initial expression of interest.
(2) Site Outreach
Conduct a pre-feasibility assessment.
Pre-identify the most suitable sites and anticipate potential challenges.
Develop feasibility questionnaire based on pre-feasibility and study protocol.
Evaluate expected site performance.
(3) Site Qualification Visit (SQV)Â
Define type of SQV based on specific study requirements and selection strategy.
Evaluate FQ and site qualifications to determine if a CRA should conduct an SQV for that site (onsite or remote).
Provide feedback based on SQV.
(4) Site SelectionÂ
Receive CRA recommendations within 24â48 hours of the SQV, with final recommendation for selection (or not) from a site selection specialist.
Fast track designation can be applied to sites whom Indero has worked with in the last 12 months, accelerating selection and lowering costs (no SQV required).
Site selected with sponsor approval.
Celebrating 25 Years of Therapeutic Excellence
For a quarter-century, Indero has been the trusted CRO partner for biotech and pharmaceutical leaders across the globe, delivering precision, reliability, and innovation in dermatology and rheumatology clinical trials.
Senior Vice President, Clinical Development Ventyx Biosciences, Inc.
“. . . From the initial synopsis development to the final stages of study conduct, the synergy between our teams was palpable and was underpinned by Inderoâs strong relationships with sites, investigators, and KOLs. . .”
Key Success Factors of Site Selection
With customized and consolidated outreach processes, Indero offers efficient and expedited site selection timelines. Hereâs what makes our site selection and management services so successful:
Competitive global budget: Including a grant plan or global fair market value (FMV)
Site list optimization: Matching pre-feasibility to interest, expertise, and capabilities
Personalized outreach: Tailoring approach for first contact
Easy contracting: Utilizing existing CDA template to avoid new contracting for sites with existing agreement
North American and European presence: Utilizing local team members and languages
Established relationships: Capitalizing on established key opinion leaders and site network relationships
Partner with Indero for Site Selection & Management
Indero is a dual-focus CRO for dermatology and rheumatology clinical trials that identifies, qualifies, and selects the most suitable sites for successful studies.
Site Selection & Management Services that Accelerate Studies
Scientific discipline. Operational efficiency. Clinical development expertise. Our site selection and management services provide the rigorous foundation, quality data, and expertise dermatology and rheumatology studies need to ensure effective execution and on-time delivery.
âMy work experience with Indero has been very positive. Their monitoring support has been crucial in achieving our research goals. So far, this partnership is a true success story. Their professionalism and expertise are commendable.â
Assoc Prof. Beata Imko-Walczuk
Copernicus Medical Center, Gdansk
Wherever Youâre Going, Weâre all in.
Need help with your next study? We want to learn more. Fill out the form on the right and one of our experts will be in touch.
Inderoâs Early Phase 1 model enables sponsors to initiate topical studies that detect early pharmacodynamic signals much sooner than traditional phase 1, using microdosing and transcriptomic analysis. This approach reduces preclinical requirements, shortens study duration from 8â12 weeks to â€3 days, and lowers costs, helping teams make informed go/no-go decisions faster.
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.